Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lexaria Bioscience (LEXX) EBITDA Margin (2017 - 2025)

Lexaria Bioscience's EBITDA Margin history spans 9 years, with the latest figure at 1543.16% for Q3 2025.

  • For Q3 2025, EBITDA Margin rose 105534.0% year-over-year to 1543.16%; the TTM value through Nov 2025 reached 2077.82%, down 59931.0%, while the annual FY2025 figure was 1693.15%, 44064.0% down from the prior year.
  • EBITDA Margin for Q3 2025 was 1543.16% at Lexaria Bioscience, up from 2156.28% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 13.92% in Q2 2022 and bottomed at 21806.81% in Q4 2023.
  • The 5-year median for EBITDA Margin is 1543.16% (2025), against an average of 3300.93%.
  • The largest annual shift saw EBITDA Margin tumbled -2001017bps in 2023 before it soared 2033507bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 14434.31% in 2021, then surged by 88bps to 1796.64% in 2022, then plummeted by -1114bps to 21806.81% in 2023, then soared by 93bps to 1471.74% in 2024, then fell by -5bps to 1543.16% in 2025.
  • Per Business Quant, the three most recent readings for LEXX's EBITDA Margin are 1543.16% (Q3 2025), 2156.28% (Q2 2025), and 1614.06% (Q1 2025).